

**ASX Announcement**

**17 April 2024**

## **Two more PANCOSIL Trial treatments using OncoSil™ device**

**Three patients have now been treated with the OncoSil™ device in the Netherlands-based PANCOSIL Investigator Initiated Clinical Trial**

### **Key Highlights**

- ✓ A further two patients have been treated in the ongoing PANCOSIL Investigator Initiated Clinical Trial.
- ✓ PANCOSIL is a Netherlands-based Investigator Initiated Clinical Trial conducted at AMC Medical Centre in Amsterdam in collaboration with OncoSil Medical.
- ✓ This Trial is testing the safety and feasibility of CT-guided percutaneous radionuclide therapy (RNT) with the OncoSil™ device in patients with non-progressive locally advanced pancreatic cancer.
- ✓ In all, 20 patients will be treated with the OncoSil™ device by percutaneous application over the course of the PANCOSIL Trial.

**Sydney, Australia – 17 April 2024:** Pancreatic cancer treatment device company **OncoSil Medical Limited (ASX:OSL)** (“OncoSil” or “the Company”) is pleased to announce that a further two patients have been treated in the PANCOSIL Investigator Initiated Clinical Trial. This Trial is examining the safety and feasibility of the OncoSil™ device utilizing percutaneous application for patients with locally advanced, unresectable pancreatic cancer.

### **Three patients have now been onboarded in PANCOSIL Trial**

Three patients have now been treated with the OncoSil™ device in the Netherlands-based PANCOSIL Investigator Initiated Clinical Trial.

The Trial’s first patient treatment involving the OncoSil™ device occurred in November 2023 (see ASX Announcement dated 29 November 2023). Now another two PANCOSIL patient treatments that utilised the device have taken place over the month of April – one of 2 April 2024, and the other on 15 April 2024.

### **PANCOSIL is targeting to develop an alternative delivery option for OncoSil™ device for non-progressive locally advanced unresectable pancreatic cancer**

PANCOSIL is a Netherlands-based Investigator Initiated Clinical Trial set up in collaboration with OncoSil Medical. It is looking at the safety and feasibility of CT-guided percutaneous radionuclide therapy (RNT) with the OncoSil™ device in patients with non-progressive locally advanced unresectable pancreatic cancer. It’s aim is to expand the user base to include the medical specialty of Interventional Radiology/Interventional Oncology.



During the RNT procedure, a radioactive agent is injected directly into the tumor to deliver internal radiation. Advantages of internal radiation compared to conventional external radiation include the possibility of delivering a higher radiation dose and sparing the surrounding structures.

In all, 20 patients will be treated with the OncoSil™ device by percutaneous application over the course of the trial. This will, in turn, expand the available users who can deliver the OncoSil™ device.

Most of the funding contribution by OncoSil has already occurred in previous quarters.

**OncoSil Medical CEO & Managing Director Nigel Lange said:** *“The treatment of an additional two patients in the PANCOSIL Investigator Initiated Clinical Trial represents another significant development in our team’s efforts to validate and develop the Company’s unique OncoSil™ device. It clearly demonstrates our continued commitment to prove the safety and feasibility of CT-guided percutaneous radionuclide therapy (RNT) with the OncoSil™ device in patients with non-progressive locally unresectable advanced pancreatic cancer. As milestones in the device’s validation process are being achieved, we are, at the same time, working hard to bring current work-in-progress regulatory approvals to a satisfactory conclusion and obtain commercial agreements.*”

#### Authorisation & Additional Information

This announcement was authorised by the Chairman of OncoSil Medical Limited.

#### For further information, please contact:

<b>Mr. Nigel Lange</b> CEO & Managing Director E: <a href="mailto:nigel.lange@oncosil.com">nigel.lange@oncosil.com</a> T: +49 16096424981	<b>Mr. Christian Dal Cin</b> CFO & Company Secretary E: <a href="mailto:c.dalcin@acclime.com">c.dalcin@acclime.com</a> T: +61 3 9824 5254	<b>Ms. Julia Maguire</b> <b>The Capital Network</b> Media and Investor Enquiries E: <a href="mailto:julia@thecapitalnetwork.com.au">julia@thecapitalnetwork.com.au</a> T: +61 2 8999 3699
--	--	---

#### About OncoSil Medical

OncoSil Medical Limited (ASX:OSL) has developed a cancer treatment device, the OncoSil™ brachytherapy device, which is a critical component of a revolutionary brachytherapy treatment for locally advanced unresectable pancreatic cancer. This type of cancer is the 12<sup>th</sup> most common cancer in men and the 11<sup>th</sup> most common cancer in women across the globe, with some 500,000 new cases of pancreatic cancer detected every year. With pancreatic cancer typically diagnosed at a later stage, it has a poor prognosis for long-term survival<sup>1</sup>.

The OncoSil™ device delivers a targeted intratumoural placement of Phosphorous-32 (<sup>32</sup>P) in the treatment of locally advanced unresectable pancreatic cancer. This occurs via injection directly into a patient’s pancreatic tumours under endoscopic ultrasound guidance and takes place in combination with gemcitabine-based chemotherapy.

The OncoSil™ device that has already received breakthrough device designation in the European Union, United Kingdom and United States for the treatment of locally advanced unresectable pancreatic cancer in combination with chemotherapy. CE Marking has additionally been granted for the OncoSil™ device, which can be marketed in the European Union, United Kingdom.

While clinical trials involving the OncoSil™ device continue to occur, the Company is simultaneously moving to commercialise this unique medical technology. It is currently approved for sale in 30+ countries including European Union, United Kingdom, Türkiye and Israel, with initial commercial pancreatic cancer treatments using the device already undertaken in Spain, Italy and Israel.

To learn more, please visit: [www.oncosil.com/](http://www.oncosil.com/)

References: 1. <https://www.wcrf.org/cancer-trends/pancreatic-cancer-statistics/>